(2 references)-
- 抗原 See all UBA7 抗体
- UBA7 (Ubiquitin-Like Modifier Activating Enzyme 7 (UBA7))
-
适用
- 人
-
宿主
- 小鼠
-
克隆类型
- 单克隆
-
标记
- This UBA7 antibody is un-conjugated
-
应用范围
- Western Blotting (WB), ELISA
- 纯化方法
- Ascitic fluid
- 免疫原
- Purified recombinant fragment of human UBE1L expressed in E. Coli.
- 克隆位点
- 5B10
- 亚型
- IgG1
- Top Product
- Discover our top product UBA7 Primary Antibody
-
anti-Ubiquitin-Like Modifier Activating Enzyme 7 (UBA7) (AA 1-1012) antibody
UBA7 适用: 人 WB, IF, IP 宿主: 兔 Polyclonal unconjugated
anti-Ubiquitin-Like Modifier Activating Enzyme 7 (UBA7) (C-Term) antibodyUBA7 适用: 人 WB, ELISA, IHC, IF, ICC 宿主: 兔 Polyclonal unconjugated
anti-Ubiquitin-Like Modifier Activating Enzyme 7 (UBA7) (C-Term) antibodyUBA7 适用: 人 WB, ELISA, IHC 宿主: 兔 Polyclonal unconjugated
anti-Ubiquitin-Like Modifier Activating Enzyme 7 (UBA7) (AA 1-1012) antibodyUBA7 适用: 人 WB, IF 宿主: 小鼠 Polyclonal unconjugated
anti-Ubiquitin-Like Modifier Activating Enzyme 7 (UBA7) antibodyUBA7 适用: 人 ELISA, IHC 宿主: 兔 Polyclonal unconjugated
anti-Ubiquitin-Like Modifier Activating Enzyme 7 (UBA7) (AA 1-1012) antibodyUBA7 适用: 人 WB 宿主: 小鼠 Polyclonal unconjugated
anti-Ubiquitin-Like Modifier Activating Enzyme 7 (UBA7) antibodyUBA7 适用: 人 WB, ELISA 宿主: 小鼠 Monoclonal 5B10 unconjugated
anti-Ubiquitin-Like Modifier Activating Enzyme 7 (UBA7) (N-Term) antibodyUBA7 适用: 人 WB, IHC (p) 宿主: 兔 Polyclonal unconjugated
anti-Ubiquitin-Like Modifier Activating Enzyme 7 (UBA7) (AA 23-238) antibodyUBA7 适用: 小鼠 WB, IHC, ICC 宿主: 兔 Polyclonal unconjugated
anti-Ubiquitin-Like Modifier Activating Enzyme 7 (UBA7) (AA 249-517) antibodyUBA7 适用: 大鼠 WB, IHC, ICC 宿主: 兔 Polyclonal unconjugated
-
- 应用备注
-
Western Bloting: 1/500 - 1/2000.
ELISA: Propose dilution 1/10000.
Not yet tested in other applications.
Determining optimal working dilutions by titration test. - 限制
- 仅限研究用
-
- 状态
- Liquid
- 储存液
- Sodium azide
- 注意事项
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 储存条件
- 4 °C
-
-
: "UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 99, Issue 6, pp. 3806-11, (2002) (PubMed).
: "A gene from human chromosome region 3p21 with reduced expression in small cell lung cancer." in: Cancer research, Vol. 52, Issue 6, pp. 1536-41, (1992) (PubMed).
-
: "UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 99, Issue 6, pp. 3806-11, (2002) (PubMed).
-
- 抗原
- UBA7 (Ubiquitin-Like Modifier Activating Enzyme 7 (UBA7))
- 别名
- UBE1L (UBA7 产品)
- 别名
- D8 antibody, UBA1B antibody, UBE1L antibody, UBE2 antibody, Ube1l antibody, 1300004C08Rik antibody, UBE1 antibody, xubc3 antibody, ubiquitin like modifier activating enzyme 7 antibody, ubiquitin-like modifier activating enzyme 7 antibody, ubiquitin conjugating enzyme E2 R2 S homeolog antibody, ubiquitin-like modifier-activating enzyme 7 antibody, UBA7 antibody, Uba7 antibody, ube2r2.S antibody, LOC100092397 antibody
- 背景
-
The modification of proteins with ubiquitin is an important cellular mechanism for targeting.
Tissue specificity: Expressed in a variety of normal and tumor cell types, but is reduced in lung cancer cell lines abnormal or short-lived proteins for degradation. Ubiquitination involves at least three classes of enzymes: ubiquitin-activating enzymes, or E1s, ubiquitin-conjugating enzymes, or E2s, and ubiquitin-protein ligases, or E3s. This gene encodes a member of the E1 ubiquitin-activating enzyme family. The encoded enzyme is a retinoid target that triggers promyelocytic leukemia (PML)/retinoic acid receptor alpha (RARalpha) degradation and apoptosis in acute promyelocytic leukemia, where it is involved in the conjugation of the ubiquitin-like interferonstimulated gene 15 protein.
Synonyms: D8, UBE2, UBA1B, UBE1L, MGC12713, UBA7 - 分子量
- 112kDa
- 基因ID
- 7318
-
You are here:
